Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GSK’s RSV vaccine candidate for older adults wins priority review from FDA 

By Brian Buntz | November 2, 2022

GSKOn the heels of winning an EU nod for its RSV vaccine marketing authorization application, GSK (LSE/NYSE:GSK) has announced that FDA has accepted a Biologics License Application for its RSV vaccine candidate for older adults.

The agency also granted priority review to the vaccine, which will clip four months off the vaccine candidate’s biologics license application (BLA) review time.

The PDUFA date for the vaccine candidate is May 3, 2023.

Several other companies are also developing RSV vaccines, including Pfizer (NYSE:PFE), Icosavax (Nasdaq:ICVX) and Moderna (Nasdaq:MRNA).

GSK said that its RSV vaccine, if approved, would be the first to protect adults 60 and over from RSV infections, which can lead to pneumonia, hospitalization and death.

While researchers have sought to develop RSV vaccines since the 1960s, no vaccine against the virus is currently available.

In granting the BLA, FDA reviewed data from a prespecified interim analysis of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) Phase 3 study.

Experts have warned that there could be a ‘tripledemic’ threat this winter season thanks to the risk of COVID-19, flu and RSV infections. The potential availability of one or more RSV vaccines by fall 2023 could help protect infants, young children and older people from the latter virus, which can be life-threatening in some cases.

In GSK’s clinical study involving adults 60 and older, the vaccine offered strong protection across the RSV A and B strains.

The company has announced the regulatory authorities in Europe and Japan have accepted regulatory submissions for the RSV vaccine.

The latest clinical trial data could indicate the GSK’s RSV vaccine candidate is more effective than Pfizer’s, according to the Financial Times. Although comparing results from disparate clinical trials is problematic, there was a substantial difference in the margin of protection in the GSK and Pfizer studies. GSK’s vaccine candidate had 82.6% overall efficacy, while Pfizer’s vaccine had an overall efficacy of 66.7%.

Despite the positive news, GSK shares dipped about 1% to $33.12.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: GSK, RSV vaccine candidate
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE